Extended Dosing Regimens for Fungal Prophylaxis.

Area of Science:

• Mycology
• Pharmacology
• Hematology

Background:

• Invasive fungal diseases (IFDs) pose significant risks for patients with hematological malignancies or undergoing stem cell transplantation.
• Antifungal chemoprophylaxis is crucial for preventing IFDs in these vulnerable populations.
• Broad-spectrum triazoles are common but have drug-drug interaction limitations.

Purpose of the Study:

• To review the rationale and supporting evidence for extended dosing regimens of intravenous antifungal agents.
• To evaluate the pharmacokinetic and pharmacodynamic basis for this strategy.
• To assess data from animal models, dose escalation studies, and clinical trials.

Main Methods:

• Literature review of pharmacokinetic and pharmacodynamic properties.
• Analysis of animal model data for efficacy and safety.
• Examination of dose escalation studies in humans.
• Review of clinical trial data supporting extended dosing.

Main Results:

• Intravenous amphotericin B and echinocandins possess suitable pharmacokinetic properties (e.g., prolonged half-life, large therapeutic window) for extended dosing.
• Preclinical and clinical data suggest feasibility and potential efficacy of extended dosing regimens.
• This strategy offers an alternative to oral triazoles, mitigating drug interaction risks.

Conclusions:

• Extended dosing of intravenous antifungal agents is a rational and expanding strategy in clinical practice for IFD prophylaxis.
• This approach warrants consideration in selected patient populations, particularly those at risk for drug-drug interactions.
• Further clinical validation may support broader adoption of extended dosing regimens.